Schering Corporation

Other

Merck Sharp + Dohme Corp.

Joel A Sequeira

Imtiaz A Chaudry

Francis M Cuss

James E Patrick

Nagamani Nagabhushan

Mitchell Cayen

Keith B Nolop

Farah J Munayyer

Elliot I Stupak

Michael A Zupon

Patricia W Kogan

Frank Guazzo

Michael Kopcha

Julianne Fassberg

David Hamilton Harris

Edward M Rudnic

Stefan Sharpe

Rebecca Galeos

Fernand Labrie

Yves M Merand

Pui-Ho C Yuen

Shashank Mahashabde

Ching-Chiang Su

Susan K Heimbecher

Julianne Berry

Marc Fournier

Lorraine Wearley

Alan S Kirschner

Syed E Abidi

Slavka Libovicova-Tarzian

Donald A Johnson

Nicholas DeAngelis

Shanshank Mahashabde

Richard K Florance

Stefan A Sharpe

Saeed Chaudhry

John L Hart

A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier is disclosed.

Antifungal composition with enhanced bioavailability

Disclosed are methods for determining the smoothness index of the interior of a metered dose container.

Determination of smoothness of canisters containing inhalable medicaments

The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.

Use of mometasone furoate for treating upper airway diseases

Use of mometasone furoate for treating airway passage and lung diseases

An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid such as a salt of ethylenediaminetetraacetic acid.

Stabilized antihistamine syrup

A liquid formulation comprising ribavirin having a longer shelf life and improved taste is disclosed.

Ribavirin syrup formulations

Aerosol formulations substantially free of chlorofluorocarbons, for oral and/or nasal administration, are described. The formulations comprise 1,1,1,2-tetrafluoroethane, a medicament, optionally an excipient and optionally a surfactant. Methods of treatment using the formulations also are described.

Non-chlorofluorocarbon aerosol formulations

Aerosol formulations substantially free of chlorofluorocarbons, for oral and/or nasal administration are described. The formulations comprise 1,1,1,2 tetrafluoroethane, a medicament, optionally an excipient and optionally a surfactant. Methods of treatment utilizing the formulations also are described.

Aerosol formulations of albuterol and 1,1,1,2-tetrafluoroethane

An aqueous nebulizer suspension contains water, mometasone furoate monohydrate, a nonionic surfactant, a soluble salt and optionally a pH buffer. The suspension may be prepared by ultrasonication or jet milling techniques.

Mometasone furoate suspensions for nebulization

Growing community of inventors

Scotch Plains, NJ, United States of America

Joel A Sequeira